Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

Published:2017-10 Issue: Volume:61 Page:108-116
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Webster Jonathan A.,Tibes Raoul,Morris Larry,Blackford Amanda L.,Litzow Mark,Patnaik Mrinal,Rosner Gary L.,Gojo Ivana,Kinders Robert,Wang Lihua,Doyle L. Austin,Huntoon Catherine J.,Karnitz Larry M.,Kaufmann Scott H.,Karp Judith E.,Smith B. Douglas

Funder

Cancer Therapy Evaluation Program

NCI grants

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference51 articles.

1. An update of current treatments for adult acute myeloid leukemia;Dombret;Blood,2016

2. Cytarabine dose for acute myeloid leukemia;Lowenberg;N. Engl. J. Med.,2011

3. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study;Karanes;Leuk. Res.,1999

4. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: cancer and leukemia group B study 19902;Stone;Leuk. Res.,2011

5. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial;Vogler;Leukemia,1994

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy;Neoplasia;2024-11

3. DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies;Blood;2024-05-23

4. Targeting the DNA damage response in hematological malignancies;Frontiers in Oncology;2024-01-29

5. Targeting the DNA Damage Response for Cancer Therapy;International Journal of Molecular Sciences;2023-11-02